Pacific Biosciences of California, Inc. (NASDAQ: PACB) went down by -0.68% from its latest closing price when compared to the 1-year high value of $7.84, while PACB stocks collected +0.27% of gains with the last five trading sessions.
Pacific Biosciences of California, Inc. (NASDAQ: PACB) Worth an Investment?
Pacific Biosciences of California, Inc. (NASDAQ: PACB) The 36 Months beta value for PACB stocks is at 2.32, while 0 of the analysts out of 5 who provided ratings for Pacific Biosciences of California, Inc. stocks as a “buy” while 0 as overweight, 5 rated it as hold and 0 as sell. The average price we get from analysts is $8.00 which is $0.66 above current price. PACB currently has a short float of 15.84% and public float of 136.6M with average trading volume of 1.41M shares.
PACB Market Performance
PACB stocks went up by 0.27% for the week, with the monthly jump of 0.27% and a quarterly performance of 3.67%, while its annual performance rate touched 197.17%. The simple moving average for the period of the last 20 days is -0.33% for PACB stocks with the simple moving average of 15.13% for the last 200 days.
Analysts’ Opinion on Pacific Biosciences of California, Inc. (NASDAQ: PACB)
Many brokerage firms have already submitted their reports for PACB stocks, with Stephens repeating the rating for PACB shares by setting it to “Equal-Weight”. The predicted price for PACB socks in the upcoming period according to Stephens is $8 based on the research report published on April 2, 2019.
Cowen, on the other hand, stated in their research note that they expect to see PACB stock at the price of $8. The rating they have provided for PACB stocks is “Outperform” according to the report published on October 19, 2018.
PACB Stocks 0.05% Far from 50 Day Moving Average
After a stumble in the market that brought PACB to its low price for the period of the last 52 weeks, Pacific Biosciences of California, Inc. was unable to take a rebound, for now settling with -6.38% of loss for the given period.
The stock volatility was left at 1.18%, however, within the period of a single month, the volatility rate increased by 0.98%, while the shares surge at the distance of +1.10% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by +0.55% upper at the present time.
In the course of the last 5 trading sessions, PACB went up by +0.27%, which changed the moving average for the period of 200 days to the total of +107.93% of gains for the stock in comparison to the 20-day moving average settled at $7.37. In addition, Pacific Biosciences of California, Inc. saw -0.81% in overturn over the period of a single year with a tendency to cut further losses.
PACB Stock Insider Trading
Reports are indicating that there were more than several insider trading activities at Pacific Biosciences of California, Inc. (PACB), starting from Phillips James Michael, who sold 7,231 shares at the price of $7.17 back on Feb 19. After this action, Rushing now owns 229,530 shares of Pacific Biosciences of California, Inc., valued at $51,817 with the latest closing price.
ORDONEZ KATHY, the Director of Pacific Biosciences of California, Inc., sold 6,933 shares at the value of $7.17 during a trade that took place back on Feb 19, which means that ORDONEZ KATHY is holding 56,767 shares at the value of $49,696 based on the most recent closing price.
PACB Stock Fundamentals
The current profitability levels are settled at -128.44 for the present operating margin and +31.92 for gross margin. The net margin for Pacific Biosciences of California, Inc. stands at -130.44. Total capital return value is set at -88.41, while invested capital returns managed to touch -89.79. Equity return holds the value -102.00%, with -64.30% for asset returns.
Based on Pacific Biosciences of California, Inc. (PACB), the company’s capital structure generated 12.85 points for debt to equity in total, while total debt to capital is set at the value of 11.39. Total debt to assets is settled at the value of 8.61 with long-term debt to equity ratio rests at 12.85 and long-term debt to capital is 11.39.
The value for Enterprise to Sales is 13.79 with debt to enterprise value settled at 0.02. The receivables turnover for Pacific Biosciences of California, Inc. is 7.14 with the total asset turnover at the value of 0.50. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.90.